NASDAQ
22.11.24
21:59 Uhr
48,170 US-Dollar
+1,770
+3,81 %
+3,81 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.11. | Tarsus Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary | 1 | Reuters | ||
| TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 13.11. | Tarsus Pharmaceuticals GAAP EPS of -$0.61 beats by $0.31, revenue of $48.1M beats by $4.92M | 1 | Seeking Alpha | ||
| 13.11. | Tarsus Pharmaceuticals, Inc: Tarsus Reports Third Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements | 80 | GlobeNewswire (Europe) | Generated $48.1 million in XDEMVY® net product sales driven by more than 41,400 bottles delivered to patients in the third quarter Strengthened payer coverage highlighted by securing the two remaining... ► Artikel lesen | |
| 13.11. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.11. | Tarsus Pharmaceuticals, Inc: Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors | 2 | GlobeNewswire (USA) | ||
| 12.11. | Earnings Outlook For Tarsus Pharmaceuticals | 2 | Benzinga.com | ||
| 06.11. | Tarsus Pharmaceuticals, Inc: Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024 | 2 | GlobeNewswire (USA) | ||
| 06.11. | Tarsus Pharmaceuticals seesaws amid report Alcon interest has cooled | 5 | Seeking Alpha | ||
| 06.11. | Tarsus Pharmaceuticals-Aktie erreicht 52-Wochen-Hoch bei 48,65 US-Dollar | 2 | Investing.com Deutsch | ||
| 06.11. | Tarsus Pharmaceuticals stock hits 52-week high at $48.65 | 1 | Investing.com | ||
| 05.11. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 05.11. | Tarsus appoints Elizabeth Yeu as its Chief Medical Officer | 1 | Seeking Alpha | ||
| 05.11. | Tarsus Pharmaceuticals, Inc: Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer | 70 | GlobeNewswire (Europe) | IRVINE, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to address unmet medical needs and apply proven science and new technology to revolutionize... ► Artikel lesen | |
| 29.10. | Tarsus Pharmaceuticals stock hits 52-week high at $42.63 | 2 | Investing.com | ||
| 29.10. | Tarsus Pharmaceuticals gains amid takeover speculation | 13 | Seeking Alpha | ||
| 22.10. | Oppenheimer hält an Kursziel und Outperform-Rating für Tarsus trotz Umsatzprognose fest | 3 | Investing.com Deutsch | ||
| 22.10. | Oppenheimer retains stock target, outperform on Tarsus amid sales projection | 1 | Investing.com | ||
| 17.10. | Tarsus taps actor Betsy Sodaro to embody a 'mitey problem' in 1st Xdemvy DTC TV ad | 2 | FiercePharma | ||
| 17.10. | Tarsus Pharmaceuticals, Inc: Tarsus Launches "Your Mitey Problem," the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25% | 1 | GlobeNewswire (USA) | ||
| 04.10. | Guggenheim behält Kaufempfehlung für Tarsus-Aktien bei - Xdemvy-Markteinführung überzeugt | 3 | Investing.com Deutsch |
Seite:
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,200 | +20,00 % | EQS-AFR: Epigenomics AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Epigenomics AG
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Epigenomics AG: Vorabbekanntmachung über die... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,361 | -1,63 % | Defence Therapeutics Inc.: Defence Announces Closing of Securities for Debenture Financing | Vancouver, British Columbia--(Newsfile Corp. - November 22, 2024) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,900 | 0,00 % | Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Sees Significant Drop in Short Interest | ||
| PHIO PHARMACEUTICALS | 2,470 | -2,37 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study | --Six sites across the U.S. are now engaged in Phase1b study Marlborough, Massachusetts--(Newsfile Corp. - November 19, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 8,218 | +0,17 % | IOVANCE BIOTHERAPEUTICS, INC. - 8-K, Current Report | ||
| RECURSION PHARMACEUTICALS | 5,695 | -0,96 % | Recursion Pharmaceuticals, Inc.: Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery | Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programsPlatform will... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,070 | +6,32 % | Beam Therapeutics Inc. (NASDAQ:BEAM) Sees Large Increase in Short Interest | ||
| ROCKET PHARMACEUTICALS | 13,420 | -0,89 % | Rocket Pharmaceuticals' Gene Therapy Progress Boosts Confidence in Future Developments: Analyst | ||
| ONCOLYTICS BIOTECH | 0,915 | -3,17 % | Oncolytics Biotech Inc.: Oncolytics Biotech Reports Third Quarter 2024 Financial Results and Operational Highlights | BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational study
Upcoming... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 16,920 | -0,88 % | Arcturus Therapeutics Holdings Inc.: Arcturus Therapeutics to Present at Jefferies London Healthcare Conference | Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities... ► Artikel lesen | |
| ASSERTIO | 0,936 | -3,08 % | Assertio Holdings-Direktorin Heather Mason kauft Aktien im Wert von 60.000 US-Dollar | ||
| SIGA TECHNOLOGIES | 6,500 | +3,83 % | SIGA Technologies - TPOXX chalks up another DoD contract win | SIGA Technologies announced another contract win with the US Department of Defense (DoD), which is for the procurement of c $9m in TPOXX. This is the third DoD contract win in roughly three years for... ► Artikel lesen | |
| ADMA BIOLOGICS | 21,160 | -0,66 % | Adma Biologics CEO Adam Grossman verkauft Aktien im Wert von 1,03 Millionen US-Dollar | ||
| VIR BIOTECHNOLOGY | 7,120 | +2,45 % | Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR) | ||
| VERVE THERAPEUTICS | 4,835 | +5,11 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on October 31, 2024... ► Artikel lesen |
TARSUS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +3,81 % bei einem Aktienkurs von 48,170 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TARSUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.
